PS
INMB icon

Principal Securities’s INmune Bio INMB Stock Holding History

Principal Securities’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-619
Closed -$1.28K – 2414
2025
Q3 		$1.28K Buy
+619
New +$1.42K ﹤0.01% 3337

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return

Principal Securities's INMB Position: Q4 2025 in Review

Principal Securities sold out of INmune Bio (INMB) in Q4 2025, closing a stake of 619 shares — an estimated $1.28K sold.

Principal Securities first reported a position in INMB in Q3 2025 and held it in 1 quarter. The position peaked at $1.28K in Q3 2025. 74 funds tracked by Wall St. Rank hold INMB as of Q4 2025.

  • Principal Securities reported no remaining INmune Bio position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 619 INmune Bio shares in Q4 2025, an estimated $1.28K.
  • Principal Securities first reported a position in INmune Bio in Q3 2025 and held it in 1 quarter.
  • Principal Securities's INmune Bio position peaked at $1.28K in Q3 2025.
  • 74 funds tracked by Wall St. Rank held INmune Bio as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.